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Summary
Resistant hypertension (RH) is defined as a condition in which blood pressure remains above 140/90 mm Hg 
despite the use of at least three antihypertensive drugs, correctly combined and in full doses (including a diuretic). 
In Poland, the percentage of people suffering from RH is estimated at 10–13% relative to the total number of 
patients with hypertension. On the other hand, in recent years we have seen a significant increase in the impor-
tance of combination products both in Europe and in the United States. Several studies have shown that therapy 
that includes an average of 3 antihypertensive agents (in the form of combination products) having different 
mechanisms of action, such as blockers of the renin-angiotensin-aldosterone system (RAAS) in combination with 
a calcium channel blocker (CCB) or a diuretic, provides blood pressure control in the majority of patients, not 
only through increased efficacy and tolerability of drugs, but also owing to the simplification of the therapeutic 
regimen, which promotes the compliance with medical recommendations. In this paper we present the case of  
a patient with resistant hypertension, whose blood pressure normalised only after the use of a combination 
product.
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Introduction
Resistant hypertension remains the cause of many 
diagnostic and therapeutic problems. In this paper 
we present the case of a patient suffering from this 
type of hypertension, who has been treated without 
effect for 4 years, and who achieved a satisfactory 
hypotensive effect after the introduction of a fixed 
dose combination drug in her therapy, in accordance 
with the latest guidelines of the Polish Hypertension 
Society (PTNT).
Resistant hypertension
Resistant hypertension [RH] is defined as a condi-
tion in which blood pressure remains above 140/90 
mm Hg despite the use of 3 medicines (including a di-
uretic), correctly combined and in full doses [1, 2]. 
In addition, according to some authors, difficulties in 
lowering systolic blood pressure below 160 mm Hg 
in elderly people should also be classified as resistant 
hypertension. In Poland, the percentage of people 
suffering from resistant hypertension is estimated at 
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10–13% of the total number of patients with hyper-
tension. According to the results of the Pol-Fokus 
study published in 2015, this percentage reaches 
nearly 20%. Many authors emphasise the need to 
distinguish between true resistant and pseudo-resis-
tant hypertension. In the case of true resistant HT, 
very high systolic blood pressure values are seen, 
allowing diagnosing grade 3 HT. Furthermore, this 
type of hypertension typically occurs in the elderly, 
in obese people, with metabolic syndrome, left ven-
tricular hypertrophy, renal, thyroid and parathyroid 
gland dysfunctions, in patients using non-steroidal 
anti-inflammatory drugs, corticosteroids or sympath-
omimetics. Other causes of true resistant HT include 
excess sodium in the diet, non-taking the diuretic, 
pain syndromes, stress and smoking or drinking al-
cohol. In turn, pseudo-resistant HT is mainly asso-
ciated with non-compliance, improper treatment, 
white-coat effect, mistakes in BP measurement and 
pseudo-hypertension [3–8].
Fixed dose combination agents  
in the treatment of hypertension
In recent years, both in Europe and in the United 
States, we can see the growing importance of com-
bination products for the treatment of all types of 
hypertension, including resistant. They were used for 
the first time already in the 60s of the last century. 
So far, in the absence of a therapeutic effect of a drug 
used in monotherapy, its dose was increased. Un-
fortunately, in addition to an improved hypotensive 
effect, this method often increased the frequency of 
adverse events. According to the latest recommenda-
tions, treatment of hypertension should start with 
combination therapy with two drugs, with possible 
increase of one or both to the maximum dose [9, 10]. 
According to the 2015 PTNT Guidelines, the use 
of combination products increases the efficacy and 
tolerability of antihypertensive therapy, and also im-
proves patient compliance [1, 11].
Case report
We present a case of a patient hospitalised at the De-
partment of Internal Medicine, Medical University 
of Lublin, who suffered from resistant hypertension 
and who achieved blood pressure normalisation only 
after the use of a combination product. The 59-year-
-old patient presented to the Admission Room of the 
Ophthalmology Department because of pain in the 
head and eyeball. Blood pressure measured at that 
time was 220/120 mm Hg; therefore, the patient was 
referred to the Internal Medicine Department for 
blood pressure normalisation. Four years earlier, the 
patient was hospitalised at another centre because of 
significantly elevated blood pressure values. At that 
time, blood pressure normalisation was achieved by 
using: indapamide 1 × 1.5 mg, ramipril 1 × 10 mg, 
and nitrendipine 3 × 10 mg. In the following years, 
due to frequent headaches associated with high blood 
pressure values, the patient had been using nitrendi-
pine up to 30 mg per day plus captopril sublingually 
as necessary. Periodically she also took furosemide. It 
is difficult to assess whether blood pressure resistance 
was “true” or “pseudo”, because due to the high 
professional commitment and lack of care for her 
health, the woman could be non-compliant. How-
ever, during her stay at the Department where she 
regularly took her medication, blood pressure values 
still did not improve, suggesting a true resistance. 
Following admission to the Department, torasemide 
1 × 10 mg was additionally used; however, the anti-
hypertensive effect was unsatisfactory. On the next 
day after admission to the Department, at 8:00 AM, 
blood pressure was 150/90 mm Hg, and at 10:30 
it was 220/130 mm Hg. Long-acting metoprolol 
1 × 50 mg was added to the patient’s medication; as 
a result, blood pressure decreased to 150/90 mm Hg 
at 12:00 PM and 160/80 mm Hg at 2:00 PM. In the 
following days, blood pressure values were still unsat-
isfactory — 150/100 mm Hg and 160/100 mm Hg; 
hence doxazosin 3 × 4 mg was added to the treat-
ment regimen. Blood pressure values in the following 
days were 140/80 mm Hg, 160/90 mm Hg, 160/90 
mm Hg. The ABPM (ambulatory blood pressure 
monitoring) method was used to monitor the pa-
tient’s blood pressure. Mean 24-hour blood pressure 
was 153/80 mm Hg; for the night interval the mean 
value was 144/76 mm Hg, and for the day interval 
it was 158/83 mm Hg. Systolic blood pressure load 
was 98%, diastolic 54%, RRSmax 228 mm Hg, 
RRSmin 130 mm Hg, RRDmax 127 mm Hg, RRDmin 
50 mm Hg (Fig. 1, Table 1). As the patient’s blood 
pressure control was unsatisfactory, her antihyperten-
sive therapy was modified. Torasemide, ramipril and 
nitrendipine were discontinued, and a combination 
product containing perindopril + indapamide + am-
lodipine 10/2.5/10 mg was introduced; in addition 
to one dose of this product taken in the morning, the 
patient was taking 2 × 4 mg doxazosin and 1 × 50 mg 
long-acting metoprolol. The previously persistent 
pain of the head and eyeball completely resolved, 
and blood pressure values in the following days were 
as follows: 145/95 mm Hg, 120/80 mm Hg, 120/ 
/70 mm Hg, and 105/65 mm Hg; moreover, the pa-
arterial hypertension 2015, vol. 19, no. 3
142 www.ah.viamedica.pl
Figure 1. ABPM baseline graph (12/13 May 2015) — see Table 1
tient began to complain of orthostatic hypotension 
symptoms. Doxazosin was discontinued and ABPM 
mo nitoring was repeated — mean 24-hour blood pres-
sure was 105/61 mm Hg; for the night interval the 
mean value was 97/56 mm Hg, and for the day in-
terval it was 112/64 mm Hg. Systolic blood pressure 
load was 11%, diastolic 3%, RRSmax 145 mm Hg, 
RRSminP 80 mm Hg, RRDmax 83 mm Hg, RRDmin 
Table 1. Collective results of measurements and medications
ABPM 12/13 May 2015 ABPM 18/19 May 2015
6:00–21:59
MEAN RR, HR 158/83 mm Hg, 76/min 112/64 mm Hg, 67/min
RRSmin 130 mm Hg 95 mm Hg
RRSmax 228 mm Hg 145 mm Hg
RRDmin 50 mm Hg 46 mm Hg
RRDmax 127 mm Hg 83 mm Hg
22:00–5:59
MEAN RR, HR 144/76 mm Hg, 65/min 97/56 mm Hg
RRSmin 118 mm Hg 80 mm Hg
RRSmax 173 mm Hg 131 mm Hg
RRDmin 52 mm Hg 40 mm Hg
RRDmax 87 mm Hg 81 mm Hg
Daytime/nighttime RRS/RRD (%) 8,9%/8,4% 13,4%/12,5%
Antihypertensive medications Indapamide 1 × 1,5 mg
Ramipril 1 × 10 mg
Nitrendipine 3 × 10 mg
Torasemide 1 × 10 mg
Metoprolol ZOK 1 × 50 mg




10/2,5/10mg; 1 × 1 tablet
Metoprolol ZOK 1 × 50 mg
2 tablets/day
RRS — systolic blood pressure; RRD — diastolic blood pressure; HR — heart rate
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Figure 2. ABPM baseline graph after treatment modification (18/19 May 2015) — see Table 1
40 mm Hg (Fig. 2, Table 1). The woman was dis-
charged home in good general condition, without 
complaints, with a recommendation to reduce her 
body weight due to grade 3 obesity (BMI 43 kg/m2), 
and to take orally the combination product containing 
perindopril+indapamide+amlodipine 10/2.5/10 mg 
once daily, in addition to long-acting metoprolol 50 mg 
once daily, atorvastatin 20 mg once daily due to ab-
normal lipid profile, and metformin sustained release 
500 mg once daily at bedtime due to impaired fast-
ing glucose (IFG). Currently the patient has satisfac-
tory blood pressure values and she remains under the 
care of the Cardiology Outpatient Clinic; check-up 
30 days after discharge from the Department showed 
satisfactory blood pressure values.
Discussion
Several studies have shown that the introduction of 
an average of 3 antihypertensive agents (in the form 
of combination products) having different mecha-
nisms of action, such as blockers of the renin-angio-
tensin-aldosterone system (RAAS), in combination 
with a diuretic or CCB, in most cases allows to 
achieve target blood pressure values, which was 
confirmed in our patient, resulting in a spectacular, 
or even hypotensive effect, despite prior ineffective 
use of products with the same mechanism of ac-
tion, given separately. However, patients with RH 
and coronary artery disease can also benefit from 
products which are a combination of a CCB with 
a beta-blocker.
When deciding to initiate treatment, it should be 
determined which combination would be the most 
effective. It should be tailored to the patient’s needs. 
Concomitant diseases, such as diabetes, metabo-
lic syndrome, past myocardial infarction or stroke 
should be taken into account.
In addition to obvious pathophysiological ratio-
nale for the above combinations, their efficacy has 
been confirmed in clinical trials. An example is the 
ADVANCE study, which monitored the combina-
tion of an ACEI, perindopril, with a thiazide-like 
diuretic, indapamide. For a period of 4 years, the in-
vestigators followed-up a group of randomly selected 
patients with resistant HT and diabetes who took 
a combination product and placebo. In the group 
of patients treated with the combination product, 
all-cause mortality was reduced by 14% and cardio-
vascular mortality by 18% compared with patients 
receiving placebo. In addition, the antihypertensive 
therapy reduced the risk of micro- and macrovascular 
complications.
Furthermore, the ADVANCE CCB study demon-
strated a reduction in overall mortality by 28% in 
over 3,000 patients treated with perindopril, in-
dapamide and a CCB. 
One of the key studies evaluating the effect of 
combined perindopril and amlodipine was the 
ASCOT-BPLA study. Follow-up of the group treated 
with a combination of angiotensin-converting en-
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zyme inhibitor (ACEI) and CCB showed a decrease 
in all-cause mortality, cardiovascular mortality and 
stroke compared with the group receiving atenolol 
and a thiazide diuretic used as necessary.
Another study, in which three therapeutic strat-
egies were compared, was the STRATHE study. 
One group of patients was treated with a gradually 
increasing dose of a combination product contain-
ing perindopril and indapamide, the second group 
was treated with atenolol or losartan alone, and 
when this treatment failed, the third treatment re-
ceived a titrated dose of valsartan with addition 
of hydrochlorothiazide. Also here the best results 
were obtained for the combination products after 
9 months [12, 13].
References
1. Tykarski A., Narkiewicz K., Gaciong Z. et al. Zasady postępowa-
nia w nadciśnieniu tętniczym — 2015 rok. Wytyczne Polskiego 
Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 
w Praktyce 2015: 1: 32.
2. Calhoun D.A., Jones D., Textor S. et al. Resistant hypertension: 
diagnosis, evaluation, and treatment. A scientific statement from the 
American Heart Association Professional Education Committee of 
the Council for High Blood Pressure Research. Hypertension 2008; 
51: 1403–1419.
3. Januszewicz A., Prejbisz A. Oporne nadciśnienie tętnicze. Zasady 
postępowania w praktyce lekarskiej. Via Medica, Gdańsk 2009. 
4. Kaplan N.M. Resistant hypertension. J. Hypertens. 2005; 23: 1441–1444. 
5. Williams B. Resistant hypertension: an unmet treatment need. Lancet 
2009; 374: 1396–1398. 
6. Alderman M.H. Resistant hypertension: a clinical syndrome in search 
of a definition. Am. J. Hypertens. 2008; 21: 965–966. 
7. Szwench E., Florczak E., Prejbisz A., Kądziela J., Witkowski A., 
Januszewicz A. Oporne nadciśnienie tętnicze — postępy w diag-
nostyce i leczeniu. Kardiologia Polska 2012; 70: 66–74.
8. Tykarski A. Nadciśnienie tętnicze oporne. Choroby Serca i Naczyń 
2005; 2: 190–193.
9. Mann S.J. Drug therapy for resistant hypertension: a simplified, 
mechanistic approach J. Clin. Hypertens. 2011; 13: 120–130.
10. Moser M., Black H.R. The role of combination therapy in the 
treatment of hypertension. Am. J. Hypertens. 1998; 11: S73–S78.
11. Gaciong Z., Narkiewicz K., Tykarski A., Filipiak K.J., Opolski G. 
Miejsce gotowych połączeń lekowych w terapii nadciśnienia tętniczego 
— stanowisko ekspertów. Nadciśnienie Tętnicze 2009; 13: 363–370.
12. Woźniacka L., Posadzy-Małaczyńska A. Rola preparatów złożonych 
w terapii nadciśnienia tętniczego. Przew. Lek. 2009; 3: 58–69.
13. Gupta A.K., Arshad S., Poulter N.R. Compliance, safety, and ef-
fectiveness of fixed-dose combinations of antihypertensive agents: 
a meta-analysis. Hypertension 2010; 55: 399–407.
14. Chalmers J., Arima H., Woodward M. et al. Effects of Combination 
of Perindopril, Indapamide, and Calcium Channel Blockers in 
Patients With Type 2 Diabetes Mellitus. Results From the Action in 
Diabetes and Vascular Disease: Preterax and Diamicron Controlled 
Evaluation (ADVANCE) Trial. Hypertension 2014; 63: 259–264.
